Masoumeh Atefi, Hamid Vahedi, Mina Darand, Mohammad Hassan Entezari
{"title":"香油改善代谢功能障碍相关脂肪变性肝病女性血糖控制的生物标志物：一项随机、双盲、对照临床试验","authors":"Masoumeh Atefi, Hamid Vahedi, Mina Darand, Mohammad Hassan Entezari","doi":"10.1186/s40795-025-01123-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate whether sesame oil (SO) consumption could improve biomarkers of glycemic control, inflammation, and oxidative stress in women with metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>This randomized, double-blind, controlled trial included 60 women with MASLD (aged 20-50 years, body mass index (BMI) 25-40 kg/m²) assigned to either SO or sunflower oil (SFO) group (n = 30 each), who consumed 30 g/day for 12 weeks alongside a 500 kcal/day calorie-restricted diet. Serum fasting blood glucose (FBG), fasting serum insulin (FSI), homeostatic model assessment for insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), quantitative insulin sensitivity check index (QUICKI), serum high-sensitivity C-reactive protein (hs-CRP), and serum malondialdehyde (MDA) were measured at the pre- and post-intervention phases.</p><p><strong>Results: </strong>Compared with the control, SO supplementation led to significant improvements in FBG (mean difference: -18.2 mg/dL; 95% confidence interval (CI): -25.0 to -11.4; Cohen's d = 0.84), FSI (-3.2 µIU/mL; 95% CI: -4.5 to -1.9; d = 0.76), HOMA-IR (-1.4; 95% CI: -2.0 to -0.8; d = 0.81), HOMA-β (+ 15.6; 95% CI: +7.4 to + 23.8; d = 0.67), and QUICKI (+ 0.07; 95% CI: +0.03 to + 0.11; d = 0.72) (p < 0.05 for all). The reductions in hs-CRP (-0.05 mg/dL; 95% CI: -0.15 to + 0.05; d = 0.12) and MDA (-0.6 µmol/L; 95% CI: -1.4 to + 0.2; d = 0.28) were not significant (p > 0.05). Both groups presented significant weight loss, with no significant difference between them (p > 0.05).</p><p><strong>Conclusions: </strong>SO consumption significantly improved glycemic control biomarkers in women with MASLD, suggesting potential metabolic benefits beyond weight loss.</p><p><strong>Trial registration: </strong>This study was approved by the Institutional Review Board of Isfahan University of Medical Sciences (code: IR.MUI.</p><p><strong>Research: </strong>REC.1399.548), and it is registered at https://www.irct.ir/trial/52288 , IRCT20140208016529N6, Registration Date: 2020-12-12).</p>","PeriodicalId":36422,"journal":{"name":"BMC Nutrition","volume":"11 1","pages":"134"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228151/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial.\",\"authors\":\"Masoumeh Atefi, Hamid Vahedi, Mina Darand, Mohammad Hassan Entezari\",\"doi\":\"10.1186/s40795-025-01123-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This study aimed to investigate whether sesame oil (SO) consumption could improve biomarkers of glycemic control, inflammation, and oxidative stress in women with metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>This randomized, double-blind, controlled trial included 60 women with MASLD (aged 20-50 years, body mass index (BMI) 25-40 kg/m²) assigned to either SO or sunflower oil (SFO) group (n = 30 each), who consumed 30 g/day for 12 weeks alongside a 500 kcal/day calorie-restricted diet. Serum fasting blood glucose (FBG), fasting serum insulin (FSI), homeostatic model assessment for insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), quantitative insulin sensitivity check index (QUICKI), serum high-sensitivity C-reactive protein (hs-CRP), and serum malondialdehyde (MDA) were measured at the pre- and post-intervention phases.</p><p><strong>Results: </strong>Compared with the control, SO supplementation led to significant improvements in FBG (mean difference: -18.2 mg/dL; 95% confidence interval (CI): -25.0 to -11.4; Cohen's d = 0.84), FSI (-3.2 µIU/mL; 95% CI: -4.5 to -1.9; d = 0.76), HOMA-IR (-1.4; 95% CI: -2.0 to -0.8; d = 0.81), HOMA-β (+ 15.6; 95% CI: +7.4 to + 23.8; d = 0.67), and QUICKI (+ 0.07; 95% CI: +0.03 to + 0.11; d = 0.72) (p < 0.05 for all). The reductions in hs-CRP (-0.05 mg/dL; 95% CI: -0.15 to + 0.05; d = 0.12) and MDA (-0.6 µmol/L; 95% CI: -1.4 to + 0.2; d = 0.28) were not significant (p > 0.05). Both groups presented significant weight loss, with no significant difference between them (p > 0.05).</p><p><strong>Conclusions: </strong>SO consumption significantly improved glycemic control biomarkers in women with MASLD, suggesting potential metabolic benefits beyond weight loss.</p><p><strong>Trial registration: </strong>This study was approved by the Institutional Review Board of Isfahan University of Medical Sciences (code: IR.MUI.</p><p><strong>Research: </strong>REC.1399.548), and it is registered at https://www.irct.ir/trial/52288 , IRCT20140208016529N6, Registration Date: 2020-12-12).</p>\",\"PeriodicalId\":36422,\"journal\":{\"name\":\"BMC Nutrition\",\"volume\":\"11 1\",\"pages\":\"134\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228151/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Nutrition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40795-025-01123-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40795-025-01123-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial.
Aim: This study aimed to investigate whether sesame oil (SO) consumption could improve biomarkers of glycemic control, inflammation, and oxidative stress in women with metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods: This randomized, double-blind, controlled trial included 60 women with MASLD (aged 20-50 years, body mass index (BMI) 25-40 kg/m²) assigned to either SO or sunflower oil (SFO) group (n = 30 each), who consumed 30 g/day for 12 weeks alongside a 500 kcal/day calorie-restricted diet. Serum fasting blood glucose (FBG), fasting serum insulin (FSI), homeostatic model assessment for insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), quantitative insulin sensitivity check index (QUICKI), serum high-sensitivity C-reactive protein (hs-CRP), and serum malondialdehyde (MDA) were measured at the pre- and post-intervention phases.
Results: Compared with the control, SO supplementation led to significant improvements in FBG (mean difference: -18.2 mg/dL; 95% confidence interval (CI): -25.0 to -11.4; Cohen's d = 0.84), FSI (-3.2 µIU/mL; 95% CI: -4.5 to -1.9; d = 0.76), HOMA-IR (-1.4; 95% CI: -2.0 to -0.8; d = 0.81), HOMA-β (+ 15.6; 95% CI: +7.4 to + 23.8; d = 0.67), and QUICKI (+ 0.07; 95% CI: +0.03 to + 0.11; d = 0.72) (p < 0.05 for all). The reductions in hs-CRP (-0.05 mg/dL; 95% CI: -0.15 to + 0.05; d = 0.12) and MDA (-0.6 µmol/L; 95% CI: -1.4 to + 0.2; d = 0.28) were not significant (p > 0.05). Both groups presented significant weight loss, with no significant difference between them (p > 0.05).
Conclusions: SO consumption significantly improved glycemic control biomarkers in women with MASLD, suggesting potential metabolic benefits beyond weight loss.
Trial registration: This study was approved by the Institutional Review Board of Isfahan University of Medical Sciences (code: IR.MUI.
Research: REC.1399.548), and it is registered at https://www.irct.ir/trial/52288 , IRCT20140208016529N6, Registration Date: 2020-12-12).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
